November 12, 2020
Medicare to cover monoclonal antibody COVID-19 treatments
Editor's Note
The Centers for Medicare and Medicaid Services (CMS) on November 10 announced that Medicare will cover out-of-pocket costs for monoclonal antibody drugs for COVID-19 during the public health emergency.
The agency’s coverage includes Eli Lilly’s bamlanivimab, which recently received an emergency use authorization from the Food and Drug Administration.
Medicare won’t pay for monoclonal antibody products that providers receive for free, but it will pay for the infusion.
Free Daily News
- Study finds workforce readiness gap in new nurses
- Joint replacement manufacturer recalls products after FDA packaging warning
- Gene-edited pig kidney, heart pump combined in transplant surgery milestone
- Catheter sterility concerns prompt Class 1 FDA recall for surgery trays
- Large amounts of personal data possibly stolen in Change Healthcare cyberattack
- AI model helps predict patient decline, drive collaborative care
- One patient’s recovery highlights benefits of outpatient endoscopic spine surgery
- Getting ready for the OAS CAHPS Survey 2025 requirement
- Contribute to perioperative education with the 2024 OR Manager Salary/Career Survey
- Supply chain stability improves, but threats remain
© Access Intelligence, LLC. All rights reserved. | Privacy Policy | Diversity, Equity, Inclusion & Belonging